niacinamide and panobinostat

niacinamide has been researched along with panobinostat in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Forgione, M; Hailu, GS; Mai, A; Robaa, D; Rotili, D; Sippl, W	1
Alsinet, C; Cabellos, L; Friedman, SL; Hoshida, Y; Lachenmayer, A; Llovet, JM; Minguez, B; Thung, S; Toffanin, S; Tsai, HW; Villanueva, A; Ward, SC	1
Goertz, RS; Knieling, F; Strobel, D; Waldner, MJ	1

Reviews

1 review(s) available for niacinamide and panobinostat

Article	Year
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives. Journal of medicinal chemistry, 2017, 06-22, Volume: 60, Issue:12 Topics: Animals; Antiparasitic Agents; Drug Repositioning; Helminth Proteins; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Leishmania; Plasmodium; Protozoan Proteins; Schistosoma; Toxoplasma; Trypanosoma	2017

Other Studies

2 other study(ies) available for niacinamide and panobinostat

Article	Year
Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. Journal of hepatology, 2012, Volume: 56, Issue:6 Topics: Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellular; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Niacinamide; Panobinostat; Phenylurea Compounds; Polymorphism, Single Nucleotide; Pyridines; RNA, Messenger; Sorafenib; Survivin; Xenograft Model Antitumor Assays	2012
Quantification of dynamic contrast-enhanced ultrasound in HCC: prediction of response to a new combination therapy of sorafenib and panobinostat in advanced hepatocellular carcinoma. BMJ case reports, 2012, Dec-17, Volume: 2012 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Contrast Media; Fatal Outcome; Humans; Hydroxamic Acids; Indoles; Liver Neoplasms; Male; Neoplasm Staging; Niacinamide; Panobinostat; Phenylurea Compounds; Sorafenib; Ultrasonography	2012

Article

Year

Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

Journal of hepatology, 2012, Volume: 56, Issue:6

Topics: Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellular; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Niacinamide; Panobinostat; Phenylurea Compounds; Polymorphism, Single Nucleotide; Pyridines; RNA, Messenger; Sorafenib; Survivin; Xenograft Model Antitumor Assays

2012

Quantification of dynamic contrast-enhanced ultrasound in HCC: prediction of response to a new combination therapy of sorafenib and panobinostat in advanced hepatocellular carcinoma.

BMJ case reports, 2012, Dec-17, Volume: 2012

Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Contrast Media; Fatal Outcome; Humans; Hydroxamic Acids; Indoles; Liver Neoplasms; Male; Neoplasm Staging; Niacinamide; Panobinostat; Phenylurea Compounds; Sorafenib; Ultrasonography

2012